ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1643

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use

Madelon Vonk1, Oliver Distler 2, Daniel Furst 3, Eric Hachulla 4, Sindhu Johnson 5, Shervin Assassi 6, Leslie Meng 7, Manuel Quaresma 8, Margarida Alves 8, Emmanuelle Clerisme-Beaty 8 and Wim Wuyts 9, 1Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, 2Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 3University of California, Los Angeles, CA, 4Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, 5Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, 6Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, 7Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, 8Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 9Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoimmune diseases, interstitial lung disease, Scleroderma, therapy and fibrosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks compared with placebo (−52.4 versus −93.3 mL/year; difference 41.0 mL/year [95% CI 2.9, 79.0]; p=0.04), with adverse events that were manageable for most patients. Corticosteroids are commonly used in patients with SSc-ILD, despite a lack of evidence to support their efficacy. We assessed the efficacy and safety of nintedanib in patients who did and did not use corticosteroids in the SENSCIS trial.

Methods: Patients with SSc-ILD with ≥10% fibrosis of the lungs on HRCT were randomized to receive nintedanib 150 mg bid or placebo. Patients taking prednisone ≤10 mg/day or equivalent were allowed to participate. Lung function outcomes and adverse events (irrespective of causality) were analyzed in subgroups of patients who did and did not use corticosteroids. Corticosteroid use included use at baseline, during treatment with trial drug, and following discontinuation of trial drug (up to week 52).

Results: Of 576 patients who received trial drug, 206 (71.5%) and 191 (66.3%) patients in the nintedanib and placebo groups, respectively, used corticosteroids. Mean (SD) FVC (mL) at baseline was 2499 (814) in patients who used corticosteroids and 2501 (691) in patients who did not, and FVC % predicted was 71.9 (17.0) and 73.8 (15.9) in these groups respectively. In patients who received placebo, the mean (SE) rate of decline in FVC over 52 weeks was numerically greater in patients who used corticosteroids than in those who did not [-103.9 (16.7) versus -72.5 (23.3) mL/year]. Nintedanib reduced the annual rate of decline in FVC (mL/year) versus placebo both in patients who did and did not use corticosteroids, with no difference in the treatment effect between subgroups detected (treatment-by-time-by-subgroup interaction p=0.82) (Figure). In the nintedanib and placebo groups, respectively, absolute declines in FVC >5% predicted were seen in 22.4% and 27.2% of patients who used corticosteroids (OR 0.78 [95% CI: 0.49, 1.23]) and 15.9% and 30.9% of patients who did not use corticosteroids (OR 0.42 [95% CI: 0.20, 0.87]) (treatment-by-subgroup interaction p=0.16). The adverse event profile of nintedanib was similar between the subgroups by corticosteroid use, but the proportions of patients with nausea or vomiting adverse events were lower, and the proportion with upper respiratory tract infection was higher, in those who used corticosteroids (Table). The proportion of patients treated with nintedanib who had adverse events leading to discontinuation of study drug was similar in patients who did and did not use corticosteroids. A limitation of these analyses is that they have not been adjusted for differences between the subgroups of patients taking and not taking corticosteroids at baseline.

Conclusion: In the SENSCIS trial in patients with SSc-ILD, over two-thirds of patients used corticosteroids. Nintedanib reduced the annual rate of decline in FVC irrespective of use of corticosteroids. The adverse event profile of nintedanib was similar in patients who did and did not use corticosteroids.


Disclosure: M. Vonk, Actelion, 2, 5, 8, actelion, 2, 5, 8, Actelion Pharmaceuticals, 2, 5, 8, Boehringer Ingelheim, 5, 8, Boehringer ingelheim, 5, 8, Ferrer, 2, Ferrer International, 2, Ferrier, 2, GSK, 5, 6, Roche, 8; O. Distler, A. Menarini, 5, Abbvie, Acceleron, 5, Acceleron Pharma, 5, Actelion, 2, 5, 8, Actelion Pharmaceuticals, 2, 5, 8, 9, Amgen, 5, AnaMar, 2, 5, Bayer, 2, 5, 8, 9, Biogen Idec, 2, 5, Blade Therapeutics, 5, Boehringer Ingelheim, 2, 5, 8, 9, Catenion, 5, 9, ChemomAb, 2, 5, ChemomAB, 5, CSL Behring, 5, Ergonex, 5, espeRare Foundation, 2, 5, Genentech/Roche, 2, 5, GlaxoSmithKline, 5, GSK, 2, 5, Holds Patent mir-29 for the treatment of systemic sclerosis, 9, Inventiva, 2, 5, iQvia, 5, Italfarmaco, 2, 5, Italfarmco, 5, Lilly, 2, 5, med, 5, 8, medac, 5, Medac, 2, 5, MedImmune, 2, 5, Medscape, 5, 8, 9, Menarini, 8, Mepha, 8, Mitsubishi Tanabe, 2, 5, Mitsubishi Tanabe Pharma, 2, 5, MSD, 5, 8, Novartis, 2, 5, 8, 9, Patent, 9, Patent issued, 9, Pfizer, 2, 5, 8, Pharmacyclics, 2, 5, Roche, 5, 8, 9, Sanofi, 2, 5, Sinoxa, 2, 5, Target Bio Science, 5, Target BioScience, 5, UCB, 2, 5, 9, UCB in the area of potential treatments of scleroderma and its complications, 2, 5; D. Furst, Actelion, 2, 5, Actelion Pharmaceuticals, 2, 5, Amgen, 2, 5, BMS, 2, 5, CME, 5, 8, Corbus, 2, 5, Galapagos, 2, 5, Galapogos Novartis, 5, GlaxoSmithKline, 2, GSK, 2, 5, NIH, 2, Novartis, 2, 5, Pfizer, 2, 5, Roche/Genentech, 2, 5, Sanofi, 2, 5; E. Hachulla, Actelion, 2, 5, Bayer, 2, 5, Chugai Pharma France, 8, GSK, 2, 5, Pfizer, 2, 5, Roche SAS, 5; S. Johnson, Bayer, 2, Boehringer Ingelheim, 2, 5, Corbus, 2, Ikaria, 5, Roche, 2; S. Assassi, Bayer, 2, Boehringer Ingelheim, 2, 5, 8, Integrity Continuing Education, 8, 9, Medscape, 8, 9, Momenta, 2; L. Meng, Boehringer Ingelheim, 3; M. Quaresma, Boehringer Ingelheim, 3; M. Alves, Boehringer Ingelheim, 3; E. Clerisme-Beaty, Boehringer Ingelheim, 3; W. Wuyts, Boehringer Ingelheim, 9, Roche, 9.

To cite this abstract in AMA style:

Vonk M, Distler O, Furst D, Hachulla E, Johnson S, Assassi S, Meng L, Quaresma M, Alves M, Clerisme-Beaty E, Wuyts W. Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-nintedanib-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-subgroup-analysis-of-the-senscis-trial-by-corticosteroid-use/. Accessed January 16, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-nintedanib-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-subgroup-analysis-of-the-senscis-trial-by-corticosteroid-use/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.